Silica Corpora
About Silica Corpora
Silica Corpora GmbH is an innovative company founded in 2022 with a focus on transforming drug discovery through advanced generative technologies. Our mission is to develop advanced De Novo solutions to enhance the quality and cost-effectiveness of antibody therapeutics targeted at diseases with high unmet medical need.
Our Mission and Values
We leverage a proprietary AI-based platform to design and optimize therapeutic antibodies using amino acid sequences. Our modular system includes modules like Generator, Discriminator, Optimizer, and Ep-Mapper which work synergistically for precise, efficient, and adaptive antibody design.
We prioritize reducing animal testing, sustainable eco-friendly practices, democratizing drug discovery to make it accessible globally, and removing cost barriers for individualized therapies. Our company culture thrives on respect, growth mindset, collaboration, and continuous innovation.
Leadership Team
Our leadership includes:
- Jaime Rossello - CEO, driving company vision and strategic direction
- Dr. Anna-Catharina Krebs - Chief Scientific Officer, leading scientific innovations
- Tim Ermak, PhD, MBA - CTO, leading technological advancements
- Scientific Advisors and Business Development Advisors supporting our growth and market presence
Contact and Socials
Silica Corpora GmbH is headquartered at Am Friedrichshain 26, 10407 Berlin, Germany. We actively partner with organizations to foster innovation. Connect with us on:
